Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Filings indexed 947 across all filing types
Latest filing 2026-03-30 Major Shareholding Noti…
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
Major Shareholding Notification
2026-03-30 English
8-K Filing
Regulatory Filings
2026-02-11 English
8-K Filing
Regulatory Filings
2026-01-30 English
8-K Filing
Regulatory Filings
2026-01-05 English
4 Filing
Director's Dealing
2025-12-23 English
Director's Dealing 2025
Director's Dealing
2025-11-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.